Use of biomarkers to determine whether a subject has sustained, may have sustained or is suspected of sustaining a subacute acquired brain injury (abi)
US-2024337668-A1 · Oct 10, 2024 · US
Methods and compositions for treating neurodegenerative disorders and alzheimer's disease and improving normal memory
US8945858B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8945858-B2 |
| Application number | US-201313753402-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 29, 2013 |
| Priority date | Mar 31, 2006 |
| Publication date | Feb 3, 2015 |
| Grant date | Feb 3, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The disclosure relates generally to neurodegenerative disorders and more specifically to a group of presenilin/G-protein/c-src binding polypeptides and methods of use for modulating signaling and progression of Alzheimer's disease.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of assaying for inhibitors of Alzheimer's Disease progression comprising contacting a cell system comprising a first cell expressing βAPP and a second cell expressing PS-1 and/or PS-2 with an agent and measuring the activity of (a) Src family of tyrosine kinases, and/or (b) G oA and/or G oB interaction with PS-1 and/or PS-2. 2. The method of claim 1 , wherein the cell system comprises recombinant cells. 3. T…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Human Necessities · mapped topic
- G01N33/6896Primary
Physics · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8945858B2 cover?
- The disclosure relates generally to neurodegenerative disorders and more specifically to a group of presenilin/G-protein/c-src binding polypeptides and methods of use for modulating signaling and progression of Alzheimer's disease.
- Who is the assignee on this patent?
- Dewji Nazneen, Singer S Jonathan, Univ California
- What technology area does this patent fall under?
- Primary CPC classification G01N33/6896. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Feb 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).